Resurrect Bio is part of a new wave of ag-biotech companies focused on fixing a massive vulnerability in global food supplies: crop disease resistance. The London-based startup is building a business around restoring crops’ innate disease resistance using AI-guided gene editing and then licensing those traits to seed companies.
Resurrect Bio’s core idea is that many crops still carry the genetic machinery to fend off pathogens, but those resistance (R) genes are often suppressed or circumvented as diseases evolve. The company maps how pathogen molecules interact with plant immune receptors, then uses its “FloraFold” AI platform to predict small edits that can break those interactions and switch immunity back on. Those edits are tested in a high‑throughput in‑planta screening system, with the goal of delivering validated targets and precise edit “recipes” to breeding partners rather than developing seed brands of its own.
Commercially, Resurrect Bio positions itself as a trait discovery and licensing business. Seed companies that already have gene‑editing and breeding infrastructure can take its trait packages and integrate them into existing pipelines, with Resurrect Bio retaining IP and earning licensing income and downstream royalties. The company emphasizes that many of its proposed edits are minimal, sometimes at the level of a single base change, which could be important as regulators continue to differentiate gene‑edited traits from traditional GM events.
Resurrect Bio is a spin‑out from The Sainsbury Laboratory in Norwich and is now based at Imperial College London and has attracted both venture and strategic capital. An early seed round of roughly $2 million led by SynBioVen, with participation from UKI2S, AgFunder, and the SHAKE Climate Change Accelerator, funded platform development and early proof‑of‑concept work. In early 2026, Resurrect Bio announced an $8.1 million initial close of its Series A, led by Corteva Agriscience through its Corteva Catalyst platform and joined by Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder. Alongside the equity investment, Corteva and Resurrect Bio disclosed a collaboration to apply these disease‑resistance traits in corn, signaling a focus on large global row‑crop markets.
If in‑plant immunity can reliably reduce fungicide and pesticide use while preserving yield, it would represent a paradigm shift in seed trait technology. Because Resurrect Bio’s edits are focused on specific pathogen–receptor interactions, they lend themselves to modular stacking: one edit for a fungal disease, another for nematodes, another for oomycetes, and so on. In theory, this could significantly consolidate intellectual property for seed companies.
Resurrect Bio’s promise is not just the trait, but the cycle time. If it works at scale, it gives the seed industry a faster path to respond to emerging diseases. And if the regulatory pathway holds – where certain gene‑edited crops are treated differently from transgenic GMOs – disease traits could be deployed more widely and quickly. That doesn’t eliminate public or policy scrutiny, but it does reinforce a broader shift toward “precision breeding” as a mainstream tool for trait development.
Additionally, if in‑plant immunity can reliably replace a meaningful share of fungicide or nematicide use in key crops, it will change how trait value is priced and shared across the chain. Seed companies that control strong disease-resistance portfolios might capture more of the protection dollar via seed premiums and royalties, while crop protection firms could be pushed further toward complementary tools, such as RNA sprays, biologicals, or resistance‑management products. (Sources: AgFunder, FrontiersIn, WorldAgriTech, International Food Policy Research Institute)
